ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Updates on Approved CAR-Ts for Lymphomas

Moffitt Cancer Center

J. Chavez

High-Risk MCL: Recognition, Treatment, and Challenges

Preetesh Jain

ASH 2024 Insights: Zanubrutinib in Acalabrutinib-Intolerant Patients…

2024 ASH Annual Meeting Insights Hub

M. Shadman

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

Pirtobrutinib in R/R B-Cell Malignancies: Newest Data From the BRUIN…

Fox Chase Cancer Center

S. Nakhoda

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks

UChicago Medicine Best of ASCO® 2024: HL, DLBCL, MCL

UChicago Medicine Annual Practice Updates in Hematology and Oncology

A. Rojek

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Key Lymphoma Updates From ASH

Memorial Sloan Kettering Cancer Center

P. Torka

Practice-Changing Abstracts in NHL and HL From ASH 2023

UChicago Medicine

S. Smith

CLL and MCL: Experts Discuss the Use of Pirtobrutinib

MyCancerHaven

R. Vij, G. Shouse

Standards of Care and Future Directions in MCL

Martin Dreyling

ASH 2024 Insights: Acalabrutinib, Venetoclax, and Obinutuzumab in Pa…

2024 ASH Annual Meeting Insights Hub

A. Kim

Practical Updates on Advances in CLL and MCL

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

E. Chong

Advancing Lymphoma Treatment Options: From Bispecific Antibodies to …

Penn Medicine Abramson Cancer Center

M. Cook